Title : Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study.

Pub. Date : 1998

PMID : 9585171






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Metrifonate, a pro-drug that is transformed non-enzymatically into a potent inhibitor of acetylcholinesterase (AChE), has been used in the tropics for over 30 years for the treatment of schistosomiasis. Trichlorfon acetylcholinesterase (Cartwright blood group) Homo sapiens
2 Metrifonate, a pro-drug that is transformed non-enzymatically into a potent inhibitor of acetylcholinesterase (AChE), has been used in the tropics for over 30 years for the treatment of schistosomiasis. Trichlorfon acetylcholinesterase (Cartwright blood group) Homo sapiens
3 A pilot study, and Phase I and Phase II studies of metrifonate in Alzheimer"s disease (AD) patients conducted prior to the current study showed benign, dose-dependent adverse event profiles consisting primarily of gastrointestinal events, optimal daily dosing with a loading phase (in the absence of a loading dose phase, 6-8 weeks were required to attain steady-state AChE inhibition levels), and an improvement in Alzheimer"s Disease Assessment Scale (ADAS) scores. Trichlorfon acetylcholinesterase (Cartwright blood group) Homo sapiens